Agios Pharmaceuticals (AGIO) Profit After Tax (2012 - 2026)

Agios Pharmaceuticals has reported Profit After Tax for 15 years, with the latest figure at -$99.1 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax fell 11.0% year-over-year to -$99.1 million; the trailing twelve-month figure through Mar 2026 stood at -$422.6 million (down 163.46% YoY), and the FY2025 full-year result was -$412.8 million, down 161.27% from the prior year.
• Profit After Tax for Q1 2026 stood at -$99.1 million, up from -$108.0 million in the prior quarter.
• The five-year high for Profit After Tax was $947.9 million in Q3 2024, with the low at -$112.0 million in Q2 2025.
• Historically, Profit After Tax has averaged -$24.8 million across 5 years, with a median of -$91.8 million in 2022.
• Annual changes were most pronounced in 2023 — Profit After Tax tumbled 362.66% — and 2024, when it jumped 1137.97%.
• Agios Pharmaceuticals' Profit After Tax stood at $36.5 million in 2022, then plunged by 362.66% to -$95.9 million in 2023, then retreated by 0.61% to -$96.5 million in 2024, then dropped by 11.93% to -$108.0 million in 2025, then increased by 8.26% to -$99.1 million in 2026.
• The last three Profit After Tax figures came in at -$99.1 million (Q1 2026), -$108.0 million (Q4 2025), and -$103.4 million (Q3 2025), per Business Quant data.